Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 183

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 183
---

     1,284 
  
    Stock-based compensation 
     2,305,849  
     2,965,938 
  
    Interest earned on marketable securities 
     -  
     (430,993)
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current and non-current assets 
     (81,944) 
     161,800 
  
    Accounts payable and other current liabilities 
     474,057  
     (680,520)
  
    Operating lease right-of-use asset and liability, net 
     142  
     647 
  
    Net cash used in operating activities 
     (12,323,188) 
     (13,405,315)

    Cash flows from investing activities: 

    Purchase of marketable securities 
     -  
     (6,859,432)
  
    Maturity of marketable securities 
     -  
     24,000,000 
  
    Net cash provided by investing activities 
     -  
     17,140,568 

    Cash flows from financing activities: 

    Proceeds from issuance of shares of common stock and warrants 
     5,510,591  
     - 
  
    Issuance costs 
     (762,703) 
     - 
  
    Net cash provided by financing activities 
     4,747,888  
     - 

    Net (decrease) increase in cash and cash equivalents 
     (7,575,300) 
     3,735,253 

    Cash and cash equivalents at beginning of year 
     13,362,053  
     9,626,800 

    Cash and cash equivalents at end of year 
    $5,786,753  
    $13,362,053 

    Noncash investing and financing activities 

    ASC 842 lease renewal option exercise 
    $-  
    $236,506 
  
    Transaction costs in accounts payable and other current liabilities 
    $163,333  
    $-  
  
    Change in accumulated other comprehensive income 
    $-  
    $(96,434)

    Supplemental cash flow disclosures 

    Cash paid for income taxes 
    $1,600  
    $1,600 

See
accompanying notes to the consolidated financial